Abstract |
Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.
|
Authors | D Grahame Hardie |
Journal | Cancer cell
(Cancer Cell)
Vol. 23
Issue 2
Pg. 131-2
(Feb 11 2013)
ISSN: 1878-3686 [Electronic] United States |
PMID | 23410967
(Publication Type: Comment, Journal Article)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |